Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact

29 Jul 2019

• By Sten Stovall

Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes.

Swift exit — Sanofi ‘walks’ from R&D Pact investigating Lexicon’s Zynquista in diabetes • Source: Shutterstock

An acrimonious end seems to have come to the alliance between Sanofi and Lexicon Pharmaceuticals Inc. for the development of the dual SGLT1 and SGLT2 inhibitor Zynquista (sotagliflozin) in diabetes, with the French drug maker walking away from the program after seeing results of late-stage studies of the drug and the US-based pharma calling the move ”invalid" and “in breach of contract.”

Sanofi on 26 July said it was ending the partnership, established in November 2015, after seeing results of three late-stage...